Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 30;10(1):297.
doi: 10.4081/oncol.2016.297. eCollection 2016 Apr 15.

Splice Variants of Androgen Receptor and Prostate Cancer

Orazio Caffo  1 , Francesca Maines  1 , Antonello Veccia  1 , Stefania Kinspergher  1 , Enzo Galligioni  1
Affiliations
Review

Splice Variants of Androgen Receptor and Prostate Cancer

Orazio Caffo et al. Oncol Rev. .

Abstract

Over the last ten years, two new-generation hormonal drugs and two chemotherapeutic agents have been approved for the treatment of metastatic castration-resistant prostate cancer. Unfortunately, some patients have primary resistance to them and the others eventually develop secondary resistance. It has recently been suggested that the presence of androgen receptor splice variants plays a leading role in the primary and secondary resistance to the new hormonal drugs, whereas their presence seem to have only a partial effect on the activity of the chemotherapeutic agents. The aim of this paper is to review the published data concerning the role of androgen receptor splice variants in prostate cancer biology, and their potential use as biomarkers when making therapeutic decisions.

Keywords: Prostate cancer; abiraterone; cabazitaxel; enzalutamide; splice variants.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: OC received honoraria from Sanofi Aventis, Janssen, Bayer and Astellas. The other authors do not have conflict of interest to be declared.

References

    1. Chan SC, Li Y, Dehm SM. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 2012;287:19736-49. - PMC - PubMed
    1. Huggins C, Hodges C. Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7. - PubMed
    1. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467-79. - PubMed
    1. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45. - PubMed
    1. Marques RB, Dits NF, Erkens-Schulze S, et al. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 2010;5:e13500. - PMC - PubMed